Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this cross-sectional study of patients with wet AMD who received ā„1 anti-VEGF injection (excluding brolucizumab), evidence was generated to describe the period prevalence of specific ocular AEs. The study was conducted using the IRIS Registry, and all results were based on the study period from 01/01/2019 to 12/31/2019.
This was a retrospective cohort study of eyes in adult patients with a diagnosis of wet AMD who were treated with anti-VEGF agents from 01/01/2019 to 12/31/2019.
IRIS Registry data from 01/01/2019 to 12/31/2019 for patients with a diagnosis of wet AMD who were treated with ā„1 anti-VEGF agent (excluding brolucizumab) were included.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Aflibercept | Patients/patient eyes who were treated only with aflibercept in 2019 |
| |
| Ranibizumab | Patients/patient eyes who were treated only with ranibizumab in 2019 |
| |
| Bevacizumab | Patients/patient eyes who were treated only with bevacizumab in 2019 |
| |
| ā„2 Different Anti- VEFGFs | Patients/patient eyes who were treated with ā„2 different anti-VEGFs in 2019 |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aflibercept | Other | intravitreal injection |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with Intraocular Inflammation (IOI) Adverse events (AEs) who were treated with anti-VEGF agents | Period prevalence of IOI in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period in 2019 was assessed. | earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019 |
| Measure | Description | Time Frame |
|---|---|---|
| Age | Age information was reported | earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019 |
| Gender information | Gender information was reported |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
IRIS Registry data from 01/01/2019 to 12/31/2019 for patients with a diagnosis of wet AMD who were treated with ā„1 anti-VEGF agent (excluding brolucizumab) were included.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | East Hanover | New Jersey | 07936-1080 | United States |
Not provided
| Label | URL |
|---|---|
| Results for CRTH258AUS20 from the Novartis Clinical Trials Website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
| Ranibizumab | Other | intravitreal injection |
|
|
| Bevacizumab | Other | intravitreal injection |
|
|
| earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019 |
| Number of patients at various Patient Region | Patient regions: Northeast, Midwest, South, West, Unknown | earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019 |
| Number of patients with Insurance type | Private, Medicare, Medicare Advantage, Medicaid, Other | earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019 |
| Number of patients with Laterality of wet Age-related macular degeneration (AMD) | Laterality of wet AMD: Unilateral, Bilateral | Index date (defined as the date of first injection - 01/01/2019) |
| Number of patient eyes with the Provider specialty on date of first anti-VEGF injection | The following types were included: Retina specialist, General ophthalmologist | earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019 |
| Number of patient eyes treated with anti-VEGF agent | The following types were included OD [eye, right], OS [eye, left], Unspecified | Index date (defined as the date of first injection - 01/01/2019) |
| Number of anti-VEGF injections | Anti-VEGF utilization in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period was assessed. Measured at the patient level and patient-eye level. | over a one-year period from 01/012019 to 31/12/2019 |
| Number of patients with other ocular AEs in patients with wet AMD who were treated with anti-VEGF agents (excluding brolucizumab) | The following types were included:
| over a one-year period from 01/012019 to 31/12/2019 |
| ID | Term |
|---|---|
| D008268 | Macular Degeneration |
| ID | Term |
|---|---|
| D012162 | Retinal Degeneration |
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C533178 | aflibercept |
| D000069579 | Ranibizumab |
| D000068258 | Bevacizumab |
| D056687 | Off-Label Use |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D011307 | Drug Prescriptions |
| D004358 | Drug Therapy |
| D013812 | Therapeutics |
Not provided
Not provided